Published On: 12/4/2024
ACG 2024 Research: Presentation by Evan S. Dellon, MD, MPH
Lead author and professor of medicine in the division of gastroenterology and hepatology and director of the center for esophageal diseases and swallowing at the University of North Carolina School of Medicine, Evan S. Dellon, MD, MPH, presented a new Target RWE study at ACG 2024 titled, “Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.”
This study delves into a real-world analysis of EoE treatment patterns. We explore the factors associated with patients who do not receive medication, even after diagnosis. Watch Dr. Dellon discuss our latest research findings.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
04/03/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data -
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry) -
03/07/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies -
02/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data